Do analysts rate ICCC or ENTA?

Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 71.84%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Do analysts prefer ICCC or XFOR?

X4 Pharmaceuticals has a consensus price target of $9.38, indicating a potential upside of 134.08%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 X4 Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts rate ICCC or SNDL?

SNDL has a consensus price target of $5.00, indicating a potential upside of 243.64%. Given SNDL's stronger consensus rating and higher possible upside, analysts plainly believe SNDL is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SNDL 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher valuation and earnings, ICCC or SNDL?

ImmuCell has higher earnings, but lower revenue than SNDL. ImmuCell is trading at a lower price-to-earnings ratio than SNDL, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ImmuCell $29.93M 2.99 -$1.04M -$0.06 N/A SNDL $677.32M 0.55 -$11.29M -$0.03 N/A

Is ICCC or SNDL more profitable?

SNDL has a net margin of -1.19% compared to ImmuCell's net margin of -1.82%. SNDL's return on equity of -1.02% beat ImmuCell's return on equity. Company Net Margins Return on Equity Return on Assets ImmuCell -1.82% -1.88% -1.22% SNDL -1.19% -1.02% -0.85%

Do analysts prefer PBYI or ICCC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend LRMR or ICCC?

Larimar Therapeutics currently has a consensus price target of $15.29, suggesting a potential upside of 381.44%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than ImmuCell. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Larimar Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.09 ImmuCell 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

ImmuCell (ICCC) Competitors

$9.90 -0.15 (-1.44%)

As of 01:21 PM Eastern

Compare

ICCC vs. ENTA, XFOR, SNDL, PBYI, and LRMR

Should you buy ImmuCell stock or one of its competitors? MarketBeat compares ImmuCell with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ImmuCell include Enanta Pharmaceuticals (ENTA), X4 Pharmaceuticals (XFOR), SNDL (SNDL), Puma Biotechnology (PBYI), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical products" industry.

How does ImmuCell compare to Enanta Pharmaceuticals?

ImmuCell (NASDAQ:ICCC) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

In the previous week, Enanta Pharmaceuticals had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Enanta Pharmaceuticals and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.44 beat Enanta Pharmaceuticals' score of 0.76 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Positive
Enanta Pharmaceuticals	Positive

13.5% of ImmuCell shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 5.7% of ImmuCell shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmuCell has higher earnings, but lower revenue than Enanta Pharmaceuticals. ImmuCell is trading at a lower price-to-earnings ratio than Enanta Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$29.93M	2.99	-$1.04M	-$0.06	N/A
Enanta Pharmaceuticals	$69.21M	4.96	-$81.89M	-$2.59	N/A

Enanta Pharmaceuticals has a consensus price target of $20.29, suggesting a potential upside of 71.84%. Given Enanta Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

ImmuCell has a net margin of -1.82% compared to Enanta Pharmaceuticals' net margin of -89.56%. ImmuCell's return on equity of -1.88% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

ImmuCell has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

Enanta Pharmaceuticals beats ImmuCell on 10 of the 16 factors compared between the two stocks.

How does ImmuCell compare to X4 Pharmaceuticals?

ImmuCell (NASDAQ:ICCC) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

13.5% of ImmuCell shares are owned by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, X4 Pharmaceuticals had 2 more articles in the media than ImmuCell. MarketBeat recorded 2 mentions for X4 Pharmaceuticals and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.44 beat X4 Pharmaceuticals' score of 0.72 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Positive
X4 Pharmaceuticals	Positive

ImmuCell has higher earnings, but lower revenue than X4 Pharmaceuticals. ImmuCell is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$29.93M	2.99	-$1.04M	-$0.06	N/A
X4 Pharmaceuticals	$35.11M	10.76	-$79.20M	-$4.54	N/A

ImmuCell has a net margin of -1.82% compared to X4 Pharmaceuticals' net margin of -1,106.30%. ImmuCell's return on equity of -1.88% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%

ImmuCell has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, X4 Pharmaceuticals has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

X4 Pharmaceuticals has a consensus price target of $9.38, indicating a potential upside of 134.08%. Given X4 Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe X4 Pharmaceuticals is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ImmuCell and X4 Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does ImmuCell compare to SNDL?

ImmuCell (NASDAQ:ICCC) and SNDL (NASDAQ:SNDL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, SNDL had 5 more articles in the media than ImmuCell. MarketBeat recorded 5 mentions for SNDL and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.44 beat SNDL's score of 1.06 indicating that ImmuCell is being referred to more favorably in the media.

Company	Overall Sentiment
ImmuCell	Positive
SNDL	Positive

SNDL has a consensus price target of $5.00, indicating a potential upside of 243.64%. Given SNDL's stronger consensus rating and higher possible upside, analysts plainly believe SNDL is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
SNDL	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

13.5% of ImmuCell shares are owned by institutional investors. 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

ImmuCell has higher earnings, but lower revenue than SNDL. ImmuCell is trading at a lower price-to-earnings ratio than SNDL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmuCell	$29.93M	2.99	-$1.04M	-$0.06	N/A
SNDL	$677.32M	0.55	-$11.29M	-$0.03	N/A

ImmuCell has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, SNDL has a beta of 0.91, indicating that its stock price is 9% less volatile than the broader market.

SNDL has a net margin of -1.19% compared to ImmuCell's net margin of -1.82%. SNDL's return on equity of -1.02% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmuCell	-1.82%	-1.88%	-1.22%
SNDL	-1.19%	-1.02%	-0.85%

Summary

SNDL beats ImmuCell on 11 of the 16 factors compared between the two stocks.

How does ImmuCell compare to Puma Biotechnology?

Puma Biotechnology (NASDAQ:PBYI) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Puma Biotechnology has a net margin of 10.69% compared to ImmuCell's net margin of -1.82%. Puma Biotechnology's return on equity of 20.30% beat ImmuCell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	10.69%	20.30%	12.05%
ImmuCell	-1.82%	-1.88%	-1.22%

Puma Biotechnology has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Puma Biotechnology has higher revenue and earnings than ImmuCell. ImmuCell is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$228.40M	1.52	$31.11M	$0.48	14.18
ImmuCell	$29.93M	2.99	-$1.04M	-$0.06	N/A

In the previous week, Puma Biotechnology had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Puma Biotechnology and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.44 beat Puma Biotechnology's score of 0.94 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Overall Sentiment
Puma Biotechnology	Positive
ImmuCell	Positive

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 22.2% of Puma Biotechnology shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Puma Biotechnology beats ImmuCell on 12 of the 14 factors compared between the two stocks.

How does ImmuCell compare to Larimar Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

91.9% of Larimar Therapeutics shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 5.7% of ImmuCell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Larimar Therapeutics has a net margin of 0.00% compared to ImmuCell's net margin of -1.82%. ImmuCell's return on equity of -1.88% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
ImmuCell	-1.82%	-1.88%	-1.22%

ImmuCell has higher revenue and earnings than Larimar Therapeutics. ImmuCell is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
ImmuCell	$29.93M	2.99	-$1.04M	-$0.06	N/A

In the previous week, Larimar Therapeutics had 1 more articles in the media than ImmuCell. MarketBeat recorded 1 mentions for Larimar Therapeutics and 0 mentions for ImmuCell. ImmuCell's average media sentiment score of 1.44 beat Larimar Therapeutics' score of 0.54 indicating that ImmuCell is being referred to more favorably in the news media.

Company	Overall Sentiment
Larimar Therapeutics	Positive
ImmuCell	Positive

Larimar Therapeutics currently has a consensus price target of $15.29, suggesting a potential upside of 381.44%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Larimar Therapeutics is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Larimar Therapeutics has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

Larimar Therapeutics beats ImmuCell on 9 of the 16 factors compared between the two stocks.

Get ImmuCell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ICCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ICCC vs. The Competition

Export

Metric	ImmuCell	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$89.61M	$8.21B	$6.43B	$12.45B
Dividend Yield	N/A	2.61%	2.69%	5.22%
P/E Ratio	-165.06	15.68	23.85	24.37
Price / Sales	2.99	7.10	522.03	117.40
Price / Cash	50.78	17.10	41.27	57.13
Price / Book	3.31	3.64	10.04	6.75
Net Income	-$1.04M	$224.05M	$3.56B	$337.03M
7 Day Performance	0.05%	0.41%	-0.82%	0.08%
1 Month Performance	N/A	N/A	N/A	-1.66%
1 Year Performance	46.74%	2.77%	28.88%	34.01%

ImmuCell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ICCC ImmuCell	0.9162 of 5 stars	$9.91 -1.4%	N/A	+46.3%	$89.61M	$29.93M	N/A	70	Positive News Short Interest Decrease
ENTA Enanta Pharmaceuticals	2.3048 of 5 stars	$13.19 -2.5%	$20.29 +53.8%	+56.3%	$383.57M	$65.32M	N/A	160
XFOR X4 Pharmaceuticals	3.1791 of 5 stars	$4.03 +0.8%	$8.50 +110.9%	+0.3%	$380.11M	$9.01M	N/A	80	Analyst Forecast
SNDL SNDL	3.4977 of 5 stars	$1.45 +0.7%	$5.00 +244.8%	+10.2%	$373.23M	$937.39M	N/A	2,751	Positive News
PBYI Puma Biotechnology	1.2654 of 5 stars	$7.31 +0.6%	N/A	+105.1%	$372.08M	$228.40M	15.23	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ICCC) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ImmuCell (ICCC) Competitors

ICCC vs. ENTA, XFOR, SNDL, PBYI, and LRMR

How does ImmuCell compare to Enanta Pharmaceuticals?

Summary

How does ImmuCell compare to X4 Pharmaceuticals?

Summary

How does ImmuCell compare to SNDL?

Summary

How does ImmuCell compare to Puma Biotechnology?

Summary

How does ImmuCell compare to Larimar Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ImmuCell (ICCC) Competitors

ICCC vs. ENTA, XFOR, SNDL, PBYI, and LRMR

How does ImmuCell compare to Enanta Pharmaceuticals?

Does the media prefer ICCC or ENTA?

Do institutionals & insiders hold more shares of ICCC or ENTA?

Which has stronger valuation & earnings, ICCC or ENTA?

Do analysts rate ICCC or ENTA?

Is ICCC or ENTA more profitable?

Which has more volatility & risk, ICCC or ENTA?

Summary

How does ImmuCell compare to X4 Pharmaceuticals?

Do institutionals and insiders believe in ICCC or XFOR?

Does the media prefer ICCC or XFOR?

Which has preferable valuation & earnings, ICCC or XFOR?

Is ICCC or XFOR more profitable?

Which has more risk & volatility, ICCC or XFOR?

Do analysts prefer ICCC or XFOR?

Summary

How does ImmuCell compare to SNDL?

Does the media prefer ICCC or SNDL?

Do analysts rate ICCC or SNDL?

Do insiders & institutionals believe in ICCC or SNDL?

Which has higher valuation and earnings, ICCC or SNDL?

Which has more volatility and risk, ICCC or SNDL?

Is ICCC or SNDL more profitable?

Summary

How does ImmuCell compare to Puma Biotechnology?

Do analysts prefer PBYI or ICCC?

Is PBYI or ICCC more profitable?

Which has more volatility and risk, PBYI or ICCC?

Which has stronger earnings & valuation, PBYI or ICCC?

Does the media refer more to PBYI or ICCC?

Do institutionals & insiders hold more shares of PBYI or ICCC?

Summary

How does ImmuCell compare to Larimar Therapeutics?

Do institutionals and insiders hold more shares of LRMR or ICCC?

Is LRMR or ICCC more profitable?

Which has stronger valuation and earnings, LRMR or ICCC?

Does the media favor LRMR or ICCC?

Do analysts recommend LRMR or ICCC?

Which has more volatility and risk, LRMR or ICCC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ICCC vs. The Competition

ImmuCell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools